"Comparative efficacy of eritoran, a toll-like receptor 4 antagonist, in patients with severe sepsis and higher risk of mortality by type of causative pathogen" by Mark Tidswell, MD

Article

Comparative efficacy of eritoran, a toll-like receptor 4 antagonist, in patients with severe sepsis and higher risk of mortality by type of causative pathogen

All Scholarly Works

Mark Tidswell, MD, Baystate Health

Document Type

Presentations, Research

Publication Date

1-1-2010

Citation Information

LaRosa S, Tidswell M. Comparative efficacy of eritoran, a toll-like receptor 4 antagonist, in patients with severe sepsis and higher risk of mortality by type of causative pathogen. Society of Critical Care Medicine Critical care Congress. San Diego, CA. 2010.